Subgroup of ovarian cancer patients with hyperactive RAS network signaling identified: dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors

Stefano Rossetti, Aaron Broege, Joanna Sabat, Shu Wiley, Salmaan Khan, Catherine Kuzmicki, Ian MacNeil, Brian Sullivan, Lance Laing

Ovarian Cancer Research Program

Background

Screening regulatory mutations (SPM) and their phospholipidylation have not been linked to cancer, including ovarian cancer (OC) progression. An SPM and PI3K/mTOR network activity pathway activity test was developed to activate SPM in living tumor cells through PI3K or other PI3K effectors to show oncogenic signaling. In this study, we developed a novel test to show oncogenic signaling of SPM in living tumor cells.

Methods

CELsignia analysis

Figure 3: LPA initiated activity measured by CELsignia in OC cell lines

Results

Figure 2: LPA initiated activity measured by CELsignia in OC cell lines

Figure 4: Estimating LPA signal cutoffs

Summary of Results

Conclusions

References